When the sun is out after a long winter, every one loves it. But not the people of Canary Islands. Tourists there are being warned about the "unusually high risk" of UV rays this week. The Ministry of Health for this holiday destination has urged both, residents and visitors to take extra precautions and preventative measures to limit the impact of sun exposure over their body and skin.

The Ministry observed Aemet, Spain's national weather agency for the forecast which showed higher than normal UV or ultraviolet radiation levels in the region. It is in this backdrop that everyone in the region are requested to be extra careful when they are out in the sun. UV levels are set to reach 7, which is a 'high risk' in La Palma, El Hierro, La Gomera and Gran Canaria. Other regions like Tenerife, Fuerteventura and Lanzarote are expected to reach a level 6, which is also classed as 'high risk'.

UV Index Explained

As per the World Health Organization (WHO), a UV index is a measure of the level of UV radiation, which ranges from zero upward. The higher the UVI, the greater potential for damage to skin and eye and the less time it takes for harm to occur, notes WHO.

The range 1 to 2 represents a low risk, 2 to 5 is moderate, 6 to 7 is at high risk, 8 to 10 is at very high and anything over 11 is extremely risky for anyone to stay out.

UV radiation levels fluctuate throughout the day, with the highest values occurring during the four-hour period around solar noon. The reported UV Index (UVI) typically reflects this daily peak. Depending on geographic location and the use of daylight saving time, solar noon falls between 12 p.m. and 2 p.m. In some countries, sun protection advisories are issued when UV levels are expected to reach 3 or higher, as exposure at these levels increases the risk of skin damage, making protective measures essential.

What happens to you when you are out in sun for too long?

While sun bathing is good, being out in the sun when the UVI indicates a high or very high risk, may cause you health concerns. It can lead to sunburn, premature skin aging, incresed risk of skin cancer, eye damage and in severe cases, heat related disease.

Sunburn

It is one of the most common skin injury which happens when there is excess exposure to UV radiation from the sun. This happens when the UV radiation directly damages the DNA skin cells. These damaged cells die and shed, this is why people experience peeling after getting a sunburn.

Dehydration

This is also a common occurrence when your body loses too many fluids or electrolytes. It can also interfere with your normal body functions. You may feel dehydrated, especially when you are out in the sun, but not well hydrated. The most common symptoms are dizziness, fatigue and headache on hot days.

Hyponatremia

This is an electrolyte disorder in which your body experiences low sodium in blood. The symptoms could lead to nausea, confusion and even weakness. There are extreme cases when one may have seizures, slip into coma or die.

Heat Exhaustion

This is one of the most common consequence of being out under the hot sun. Dehydration with prolonged heat exposure can lead to heat exhaustion.

Heatstroke

When you are out under the sun and your body's core temperature cross 104°, heatstroke may occur. This is also known as sunstroke. As per the Centers for Disease Control and Prevention (CDC), it causes more than 600 deaths each year in the United States.

Sexually transmitted infections (STIs) such as gonorrhea and syphilis have hit record levels in Europe in over a decade, according to new data from the European Centre for Disease Prevention and Control (ECDC).

As per the agency’s latest Annual Epidemiological Reports, there has been a sharp surge in bacterial STIs across Europe. It showed that the notifications of gonorrhea and syphilis, alongside congenital syphilis in 2024, reached their highest levels in over a decade, reflecting sustained transmission across multiple countries.

The ECDC blamed the "widening gaps in testing and prevention” behind the spike in STIs. It also called for urgent targeted action to prevent further spread, including among women of reproductive age.

STI Cases Continue To Climb

The data for 2024 show that:

• gonorrhea cases reached 106,331, representing a 303 per cent increase since 2015.
• syphilis cases more than doubled over the same period to 45,577 cases.
• chlamydia remains the most frequently reported STI with 213,443 cases.
• lymphogranuloma venereum (LGV) also continued to see ongoing transmission, with 3,490 reported cases.

Bruno Ciancio, Head of Unit, Directly Transmitted and Vaccine-Preventable Diseases, said that left untreated, “these infections can cause severe complications, such as chronic pain and infertility and, in the case of syphilis, problems with the heart or nervous system”.

“Most distressingly, between 2023 and 2024, we have seen a near doubling of congenital syphilis, where infections pass directly to newborns, leading to potentially lifelong complications,” Ciancio added.

Disproportionately Affected Groups

Transmission trends vary significantly across different population groups, the ECDC said.

Men who have sex with men remain the most disproportionately affected group, with the steepest long-term increases in gonorrhea and syphilis.

Among heterosexual populations, syphilis is rising, particularly among women of reproductive age, the consequences of which are a near doubling of congenital syphilis cases from 78 in 2023 to 140 in 2024 across 14 countries reporting data.

ECDC Calls For Urgent Action

Reversing increasing trends in STI cases requires accessible prevention services, easier access to testing, faster treatment, and stronger partner notification to stop onward transmission.

The ECDC urged public health authorities to urgently update national STI strategies and strengthen surveillance systems to better monitor the impact of prevention efforts.

“Protecting your sexual health remains straightforward. Use condoms with new or multiple partners, and get tested if you have symptoms, such as pain, discharge, or an ulcer,” Ciancio said.

UK Rolls Out Gonorrhea Vaccine

In the wake of increasing gonorrhea cases, the UK in 2025 rolled out a new vaccine. The vaccine, available at sexual health clinics across England, is being offered to people who are at the highest risk of getting gonorrhea.

This includes gay and bisexual men who have recently had multiple sexual partners and another bacterial STI within the last year. This new program is expected to protect thousands of people and save the NHS over £7.9 million in the next decade.

Gonorrhea Cases Also Rising In The US

Gonorrhea is also increasing in the US, with the 2025 data from the Centers for Disease Control and Prevention showing that reported cases of gonorrhea, chlamydia, and syphilis have climbed by nearly 90 per cent since 2004. In 2023 alone, the country recorded more than 2.4 million cases of sexually transmitted infections.

The United States Food and Drug Administration (FDA) in December last year approved two new oral antibiotics to treat gonorrhea: Zoliflodacin and Gepotidacin. These approvals represent the first entirely new gonorrhea treatments in more than three decades.

Retatrutide, Eli Lilly’s new weight-loss drug, is in the final stages of its clinical trial, and the results seem very promising, the drugmaker said on Thursday. In a news release, they disclosed that the brand-new drug helped people lose up to 30 per cent of their body weight, which is about 85 pounds. The results are on a par with bariatric surgery, which helps people shed approximately 25 to 35 per cent of their total body weight within one to two years. Doctors say that this is the largest weight loss ever witnessed in a medical trial. While Lilly has not yet filed for approval from the Food and Drug Administration, the pharma giant says that it expects to file this year.

What is Retatrutide?

Retatrutide is similar to drugs like Zepbound and Wegovy that mimic the GLP-1 hormone. Retatrutide, however, along with GLP-1, mimics glucagon as well, thereby working like a triple agonist. This is unlike Zepbound, which is a double agonist. Researchers said that they have witnessed the impact of semaglutide and tirzepatide. However, Retatrutide's results went beyond the current weight-loss drugs on the market.

Dr Shauna Levy, medical director of the Tulane Weight Loss Center, explained that the current GLP-1s are not good enough to induce weight loss in people dealing with severe obesity and those who have a BMI of 35. Bariatric surgery can provide the same, but it seems that Retatrutide will be far more effective for people living with a high BMI who are trying to achieve a healthy weight.

Read more: Meet Retatrutide: The Unapproved Cousin Of Ozempic That Supports Weight Loss Differently

Retatrutide's results

Retatrutide was in the third phase of its trials involving 2,300 obese or overweight participants. While the full results have not yet been released in a medical journal, participants who took the highest dose of the drug lost 28 per cent of their body weight, approximately 70 pounds. Furthermore, nearly half of the participants lost over 30 per cent of their body weight. The trial continued for 80 weeks, and a small group of severely obese patients took the drug for 104 weeks and lost about 85 pounds on average. Alternatively, patients who took high doses of Zepbound lost around 21 per cent of their body weight in 72 weeks. Wegovy users lost about 15 per cent of their weight in 68 weeks.

What were the side effects of Retatrutide?

On the downside, there were some side effects too. Retatrutide users experienced the following side effects:

1. Diarrhoea
2. Nausea
3. Constipation
4. Urinary tract infections
5. Uncomfortable skin sensations

These have, however, been seen with GLP-1 drugs.

New weight-loss drug coming soon?

Retatrutide might be the next big weight-loss drug set to hit the market soon. It aims to maximise weight-loss results with fewer side effects for users. If approved, it could be helpful for patients who are struggling to lose weight on the current versions of GLP-1 drugs.

Amid rising cases of the Ebola virus in the Democratic Republic of Congo and Uganda, India and the US have stepped up airport screening.

The latest outbreak, caused by the Bundibugyo Ebola virus, has so far affected nearly 600 people and has caused 139 suspected deaths, as per the latest update by the World Health Organization (WHO). The global health agency has also determined that the deadly outbreak is a “Public Health Emergency of International Concern (PHEIC)”.

India Issues Health Advisory

India today issued a health advisory for passengers arriving from or transiting through Ebola-affected nations. Passengers with symptoms or exposure history should immediately report to the airport health authorities before immigration clearance.

The advisory, issued by the Directorate General of Health Services (DGHS), specifically mentions travelers coming from the Democratic Republic of Congo, Uganda, and South Sudan, all of which have been categorized as "high-risk countries" by the WHO.

The advisory is displayed at the Delhi airport by the Airport Health Organization (APHO). It advises passengers to watch out for symptoms such as:

• fever,
• weakness,
• headache,
• muscle pain,
• vomiting,
• diarrhea,
• sore throat,
• unexplained bleeding.

It also asks travelers who had direct contact with blood or body fluids of a suspected or confirmed Ebola patient to immediately report to the airport health officer or the health desk.

According to the APHO, any traveler developing symptoms within 21 days of arrival should seek immediate medical care and inform authorities about their travel history.

India Reviews Preparedness Measures

On Wednesday, India’s Health Secretary Punya Salila Srivastava chaired a high-level review meeting with health secretaries of all states and Union territories to assess preparedness and response measures for Ebola.

Officials clarified that “no case of Ebola has been detected in India so far”.

However, after the WHO declared Ebola a Public Health Emergency, the Indian government has proactively strengthened surveillance and preparedness measures across the country as an abundant precaution, official sources had said. During the meeting, states and Union territories were advised to ensure readiness at all levels.

The 2026 India-Africa Forum Summit, scheduled for May 28 to 31, was also postponed due to the "evolving health situation in parts of Africa", India's Ministry of External Affairs announced today.

The decision was made in recognition of “the importance of ensuring the full participation and engagement of African leaders and stakeholders, and mindful of the emerging public health situation on the continent", said a joint statement issued by the Indian Ministry of External Affairs and the African Union.

US Tightens Monitoring

Meanwhile, the Centers for Disease Control and Prevention (CDC) has also been enhancing public health screening and traveler monitoring amid a growing Ebola outbreak, and non-US passport holders face entry restrictions if they have been to Uganda, the Democratic Republic of Congo, or South Sudan in the previous 21 days.

“To the American public, the risk to the United States remains low,” said Satish Pillai. “Travelers to the region should avoid contact with sick people, report symptoms immediately, and follow our travel guidance.”

A US missionary doctor infected with the Ebola virus while treating patients in DR Congo has been admitted to Charité hospital in Berlin. The patient was flown to Berlin on a special medical aircraft and then transported to the hospital in a specially designed vehicle escorted by police. The aircraft also carried six other people who had contact with the infected man.

WHO Says Vaccine Could Take Months

Tedros Adhanom Ghebreyesus said he was “deeply concerned about the scale and speed of the epidemic”. He noted that the numbers are expected to rise given the time taken to detect the virus.

The WHO says it could take up to nine months before a vaccine against this particular species of Ebola is ready.

Two possible "candidate vaccines" against the Bundibugyo species are being developed, but neither has gone through clinical trials yet, WHO advisor Dr. Vasee Moorthy said, according to the BBC.

Speaking to journalists in Geneva, Tedros said 51 cases have been confirmed in the Democratic Republic of Congo — where the first case was reported — and two in neighboring Uganda.